Navigation Links
'Pilates Day(TM)' Celebration 2008 at St. Philip's Academy, Newark, NJ Saturday May 3, 2008; 1 - 3pm
Date:4/21/2008

NEWARK, N.J., April 21 /PRNewswire/ -- Each year on the first Saturday in May, the Pilates Method Alliance(R) (PMA)(R) celebrates Pilates Day(TM).

Pilates Day was created by the PMA to bring awareness to the many benefits that Pilates provides to every age group, and to promote healthy living. Pilates Day 2008 features the PMA's groundbreaking exercise initiative 'Pilates in the Schools' at St. Philip's Academy in Newark, New Jersey.

The 'Pilates in the Schools(TM)' program, aka 'PITS', consists of a special protocol of Pilates exercises appropriate for children, developed by the PMA after extensive research.

Marggi Vangeli, a member of the PMA Board of Directors, has been teaching the Pilates protocol to the fifth grade students at St. Philip's on a weekly basis since February. The program will culminate with a special celebration on Pilates Day at the school on Saturday, May 3, 2008 from 1 - 3PM, when students will demonstrate an abbreviated Pilates mat class for parents, friends, community members and invited dignitaries. Additionally, there will be a chance for attendees to take a FREE mat class taught by Vangeli and several other PMA Certified Pilates Teachers.

Vangeli, a PMA-CPT(TM) (Certified Pilates Teacher), is enthusiastic about the opportunity to teach Pilates in an urban environment. The PITS program is designed to 'educate and motivate students, teachers and families in developing physical, emotional and social skills to handle the challenges students' experience in their home, school and community environments,' said Vangeli, quoting an official PITS information sheet.

"We were delighted to be invited to participate in this initiative," said St. Philip's Head of School, Miguel Brito. "Health and wellness is central to our holistic teaching philosophy, and this is a wonderful opportunity for our students."

"I love Pilates! Some of the moves are difficult at first, but then you learn and become stronger an
'/>"/>

SOURCE Pilates Method Alliance
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ilitch Brings New Brand of Pilates to Metro Detroit With Opening of Studio in West Bloomfield
2. Breast Cancer Survival and Heart Risk, This Week on Your Cancer Today(TM)
3. Preventing Cancer, This Week on Your Cancer Today(TM)
4. Genetics and Risk, This Week on Your Cancer Today(TM)
5. Helping Couples Fight Prostate Cancer, This Week on Your Cancer Today(TM)
6. USA TODAY Continues Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration
7. USA TODAY Concludes Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration
8. In Celebration of Breast Cancer Awareness Month, Susan G. Komen for the Cure San Diego Announces Opportunities for San Diegans to Get Involved in the Fight Against Breast Cancer
9. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
10. Hundreds to Gather for Rally in Celebration of Right to Breathe Clean Air
11. 2007 Avon Foundation Awards Celebration
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:CT Angiography Highly Accurate: Multicenter Trials Show 2Health News:CT Angiography Highly Accurate: Multicenter Trials Show 3Health News:Redesigned Blue Shield of California Website Makes Finding a Doctor Online Easier and Faster 2Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 2Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 3Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 4Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 5Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 6Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 7Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 8Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 9Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 10Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 11Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 12Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 13Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 14Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 15Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 16Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 17Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 18Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 19Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 20Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 21Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 22Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 23Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 24Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 25Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 26Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 27Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 28Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 29Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 30Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 31Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 32Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 33
Breaking Medicine Technology:Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 2Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 3Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 4Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 5Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 2Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 3Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 4Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 5Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 6Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 2Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 3Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 4Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 5Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 6Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 7Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 8Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 9Dishler Laser Institute Announces Dr Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States as Seen in Forbes Magazine 61406 1Dishler Laser Institute Announces Dr Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States as Seen in Forbes Magazine 61406 2SCM Microsystems Reports Third Quarter 2009 Results 10727 1SCM Microsystems Reports Third Quarter 2009 Results 10727 2SCM Microsystems Reports Third Quarter 2009 Results 10727 3SCM Microsystems Reports Third Quarter 2009 Results 10727 4SCM Microsystems Reports Third Quarter 2009 Results 10727 5SCM Microsystems Reports Third Quarter 2009 Results 10727 6SCM Microsystems Reports Third Quarter 2009 Results 10727 7SCM Microsystems Reports Third Quarter 2009 Results 10727 8SCM Microsystems Reports Third Quarter 2009 Results 10727 9SCM Microsystems Reports Third Quarter 2009 Results 10727 10SCM Microsystems Reports Third Quarter 2009 Results 10727 11SCM Microsystems Reports Third Quarter 2009 Results 10727 12Patients Can Now Find Their Perfect Healthcare Match at Find aTop Doc com 61398 1
Other Medicine Technology:Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 2Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 3Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 4Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 5Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 6Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 7Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 8Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 9CuraGen Presents Update on Clinical Development Program for,Belinostat 2CuraGen Presents Update on Clinical Development Program for,Belinostat 3CuraGen Presents Update on Clinical Development Program for,Belinostat 4CuraGen Presents Update on Clinical Development Program for,Belinostat 5CuraGen Presents Update on Clinical Development Program for,Belinostat 6CuraGen Presents Update on Clinical Development Program for,Belinostat 7CuraGen Presents Update on Clinical Development Program for,Belinostat 8